trial

SURPASS-2

Definition

Tirzepatide against semaglutide 1 mg in type 2 diabetes (Frías et al., NEJM 2021): HbA1c −2.30 points against −1.86, and body weight −11.2 kg against −5.7 kg over 40 weeks. The first major head-to-head between the two leaders, at a diabetes dose rather than a weight-management one.

SURPASS-2 trial deep-dive

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature. Not one of them is an AI-generated summary.

Other terms under trial

Where the evidence lives